Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Respir Care. 2023 Jul;68(7):914-926. doi: 10.4187/respcare.10542.
COPD is a chronic respiratory disease that commonly coexists with other chronic conditions. These comorbidities have been shown to influence overall disease burden and mortality in COPD, and these comorbidities have an important impact on functional status and other psychosocial factors. Mental health disorders, especially anxiety and depression are common comorbidities in COPD. However, the mechanisms and interactions of anxiety and depression in COPD are poorly understood and these conditions are often underdiagnosed. The interplay between anxiety and depression and COPD is likely multifactorial and complex. An obvious mechanism is the expected psychological consequences of having a chronic illness. However, there is increasing interest in other potential biological processes, such as systemic inflammation, smoking, hypoxia, and oxidative stress. Recognition and diagnosis of comorbid anxiety and depression in patients with COPD is often challenging because there is no consensus on the appropriate screening tools or rating scales to use in this patient population. Despite the challenges in accurate assessment of anxiety and depression, there is growing evidence to support that these comorbid mental health conditions in COPD result in worse outcomes, including poor health-related quality of life, increased exacerbations with associated health-care utilization and cost, increased functional disability, and increased mortality. There are limited data of variable quality on effective treatment and management strategies, both pharmacologic and non-pharmacologic, for anxiety and depression in COPD. However, cumulative evidence demonstrates that complex psychological and lifestyle interventions, which include a pulmonary rehabilitation component, may offer the greatest benefit. The high prevalence and negative impact of depression and anxiety highlights the need for comprehensive, innovative, and standardized chronic disease management programs for individuals with COPD.
COPD 是一种慢性呼吸系统疾病,常与其他慢性疾病共存。这些合并症已被证明会影响 COPD 的整体疾病负担和死亡率,并且对功能状态和其他社会心理因素有重要影响。心理健康障碍,尤其是焦虑和抑郁,是 COPD 的常见合并症。然而,焦虑和抑郁在 COPD 中的机制和相互作用尚未被充分理解,这些情况往往被漏诊。焦虑和抑郁与 COPD 之间的相互作用可能是多因素和复杂的。一个明显的机制是患有慢性疾病的预期心理后果。然而,人们越来越关注其他潜在的生物学过程,如全身炎症、吸烟、缺氧和氧化应激。识别和诊断 COPD 患者的合并焦虑和抑郁通常具有挑战性,因为在这一患者群体中,没有关于使用适当的筛查工具或评估量表的共识。尽管在准确评估焦虑和抑郁方面存在挑战,但越来越多的证据支持 COPD 中的这些合并精神健康状况会导致更差的结局,包括健康相关生活质量下降、与加重相关的医疗保健利用和成本增加、功能残疾增加和死亡率增加。关于 COPD 中焦虑和抑郁的有效治疗和管理策略(包括药物和非药物策略)的数据有限,且质量参差不齐。然而,累积证据表明,复杂的心理和生活方式干预措施,包括肺康复组成部分,可能会带来最大的益处。抑郁和焦虑的高患病率和负面影响突出表明需要为 COPD 患者制定全面、创新和标准化的慢性疾病管理方案。